Edwin Liu
Concepts (354)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Celiac Disease | 63 | 2025 | 293 | 10.820 |
Why?
| | Autoantibodies | 48 | 2024 | 1500 | 3.160 |
Why?
| | Transglutaminases | 28 | 2025 | 156 | 3.120 |
Why?
| | HLA-DQ Antigens | 11 | 2019 | 181 | 1.950 |
Why?
| | Diet, Gluten-Free | 11 | 2025 | 45 | 1.710 |
Why?
| | Autoimmune Diseases | 8 | 2019 | 459 | 1.610 |
Why?
| | Autoimmunity | 23 | 2024 | 908 | 1.550 |
Why?
| | GTP-Binding Proteins | 12 | 2025 | 161 | 1.440 |
Why?
| | Diabetes Mellitus, Type 1 | 47 | 2024 | 3709 | 1.420 |
Why?
| | Genetic Predisposition to Disease | 21 | 2024 | 2417 | 1.290 |
Why?
| | Insulin | 24 | 2009 | 2399 | 1.270 |
Why?
| | Peptide Fragments | 15 | 2008 | 707 | 1.260 |
Why?
| | Glutens | 10 | 2023 | 59 | 0.980 |
Why?
| | HLA-DR3 Antigen | 3 | 2015 | 80 | 0.910 |
Why?
| | Islets of Langerhans | 17 | 2017 | 803 | 0.880 |
Why?
| | Rett Syndrome | 1 | 2024 | 39 | 0.860 |
Why?
| | HLA-DR Antigens | 5 | 2017 | 228 | 0.760 |
Why?
| | Insulin Antibodies | 11 | 2013 | 105 | 0.760 |
Why?
| | Gastrointestinal Diseases | 1 | 2024 | 209 | 0.750 |
Why?
| | Nutrition Therapy | 1 | 2020 | 36 | 0.660 |
Why?
| | Genetic Testing | 6 | 2015 | 452 | 0.640 |
Why?
| | Child | 45 | 2025 | 21968 | 0.640 |
Why?
| | Pyrrolidinones | 1 | 2019 | 29 | 0.630 |
Why?
| | Child, Preschool | 32 | 2025 | 11069 | 0.620 |
Why?
| | Mice, Inbred NOD | 22 | 2013 | 601 | 0.580 |
Why?
| | Patient Compliance | 2 | 2023 | 576 | 0.570 |
Why?
| | Down Syndrome | 2 | 2023 | 490 | 0.550 |
Why?
| | Anticonvulsants | 1 | 2019 | 216 | 0.540 |
Why?
| | Mass Screening | 8 | 2024 | 1262 | 0.540 |
Why?
| | Immunoglobulin A | 9 | 2025 | 210 | 0.530 |
Why?
| | Diabetes Mellitus, Experimental | 3 | 2006 | 193 | 0.490 |
Why?
| | Infant | 27 | 2025 | 9442 | 0.470 |
Why?
| | Humans | 86 | 2025 | 136783 | 0.470 |
Why?
| | Epilepsy | 1 | 2019 | 332 | 0.470 |
Why?
| | Intestinal Mucosa | 4 | 2025 | 620 | 0.450 |
Why?
| | Caregivers | 1 | 2022 | 873 | 0.430 |
Why?
| | Anaphylaxis | 3 | 2004 | 105 | 0.430 |
Why?
| | Depression | 2 | 2022 | 1402 | 0.420 |
Why?
| | Poly I-C | 4 | 2008 | 63 | 0.410 |
Why?
| | Female | 58 | 2025 | 72840 | 0.400 |
Why?
| | Adolescent | 25 | 2025 | 21463 | 0.400 |
Why?
| | Gliadin | 3 | 2018 | 13 | 0.380 |
Why?
| | Radioimmunoassay | 3 | 2016 | 173 | 0.370 |
Why?
| | Prospective Studies | 21 | 2024 | 7583 | 0.360 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2024 | 2190 | 0.360 |
Why?
| | Male | 49 | 2025 | 67361 | 0.360 |
Why?
| | Telemedicine | 1 | 2020 | 847 | 0.360 |
Why?
| | Follow-Up Studies | 12 | 2024 | 5115 | 0.360 |
Why?
| | Jejunum | 1 | 2011 | 31 | 0.350 |
Why?
| | Adjuvants, Immunologic | 3 | 2007 | 226 | 0.340 |
Why?
| | Biopsy | 11 | 2025 | 1126 | 0.340 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 98 | 0.330 |
Why?
| | Quality of Life | 5 | 2024 | 2868 | 0.320 |
Why?
| | Sensitivity and Specificity | 9 | 2017 | 1942 | 0.310 |
Why?
| | Nutritionists | 2 | 2020 | 19 | 0.310 |
Why?
| | Risk Factors | 17 | 2024 | 10331 | 0.300 |
Why?
| | Liver Failure, Acute | 2 | 2008 | 65 | 0.300 |
Why?
| | Luminescent Measurements | 2 | 2020 | 75 | 0.300 |
Why?
| | Dietary Proteins | 2 | 2019 | 135 | 0.290 |
Why?
| | Laboratories | 1 | 2009 | 113 | 0.280 |
Why?
| | Interferon-alpha | 2 | 2005 | 198 | 0.270 |
Why?
| | Wheat Hypersensitivity | 1 | 2007 | 4 | 0.270 |
Why?
| | Mice | 32 | 2013 | 17731 | 0.270 |
Why?
| | Poly A-U | 1 | 2006 | 4 | 0.270 |
Why?
| | Immune Tolerance | 4 | 2013 | 362 | 0.250 |
Why?
| | Europe | 6 | 2017 | 414 | 0.250 |
Why?
| | T-Lymphocytes | 7 | 2008 | 1998 | 0.250 |
Why?
| | Serologic Tests | 4 | 2021 | 54 | 0.250 |
Why?
| | Time Factors | 10 | 2025 | 6792 | 0.240 |
Why?
| | HLA Antigens | 5 | 2019 | 237 | 0.230 |
Why?
| | Celiac Plexus | 1 | 2024 | 6 | 0.230 |
Why?
| | Dyspepsia | 1 | 2024 | 10 | 0.230 |
Why?
| | Predictive Value of Tests | 8 | 2025 | 2030 | 0.220 |
Why?
| | CD4 Antigens | 2 | 2003 | 141 | 0.220 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2010 | 849 | 0.220 |
Why?
| | Antibodies | 3 | 2014 | 412 | 0.220 |
Why?
| | Gastrointestinal Agents | 1 | 2024 | 65 | 0.210 |
Why?
| | Electrochemical Techniques | 2 | 2021 | 51 | 0.210 |
Why?
| | Animals | 34 | 2015 | 36768 | 0.210 |
Why?
| | Autoantigens | 6 | 2009 | 428 | 0.210 |
Why?
| | Genotype | 7 | 2019 | 1919 | 0.210 |
Why?
| | Peptides | 3 | 2018 | 980 | 0.200 |
Why?
| | Abdominal Pain | 1 | 2024 | 145 | 0.200 |
Why?
| | Endosonography | 1 | 2024 | 156 | 0.200 |
Why?
| | Diet | 4 | 2019 | 1273 | 0.200 |
Why?
| | Biomarkers | 7 | 2025 | 4158 | 0.190 |
Why?
| | Mice, Inbred BALB C | 8 | 2009 | 1267 | 0.190 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2006 | 721 | 0.190 |
Why?
| | Seasons | 1 | 2024 | 544 | 0.190 |
Why?
| | Ileal Diseases | 1 | 2001 | 13 | 0.190 |
Why?
| | Short Bowel Syndrome | 1 | 2001 | 26 | 0.180 |
Why?
| | Catheterization | 2 | 2001 | 179 | 0.180 |
Why?
| | Colonic Diseases | 1 | 2001 | 33 | 0.180 |
Why?
| | Comorbidity | 2 | 2024 | 1611 | 0.180 |
Why?
| | Proportional Hazards Models | 7 | 2019 | 1260 | 0.180 |
Why?
| | Mice, Transgenic | 7 | 2013 | 2162 | 0.170 |
Why?
| | Dietetics | 1 | 2020 | 27 | 0.170 |
Why?
| | CD4-Positive T-Lymphocytes | 7 | 2008 | 1092 | 0.160 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2022 | 548 | 0.160 |
Why?
| | Delayed Diagnosis | 1 | 2020 | 91 | 0.160 |
Why?
| | Environmental Exposure | 1 | 2024 | 576 | 0.160 |
Why?
| | Infant, Newborn | 8 | 2019 | 6046 | 0.160 |
Why?
| | Incidence | 5 | 2022 | 2788 | 0.160 |
Why?
| | Vaccines | 1 | 2004 | 406 | 0.160 |
Why?
| | Enterovirus | 1 | 2019 | 86 | 0.150 |
Why?
| | Probiotics | 1 | 2019 | 53 | 0.150 |
Why?
| | Duodenum | 3 | 2023 | 77 | 0.150 |
Why?
| | Diabetes Mellitus | 2 | 2007 | 1033 | 0.150 |
Why?
| | Immunization | 4 | 2007 | 410 | 0.150 |
Why?
| | Prevalence | 3 | 2023 | 2712 | 0.150 |
Why?
| | Risk | 3 | 2019 | 904 | 0.150 |
Why?
| | Risk Assessment | 8 | 2020 | 3429 | 0.140 |
Why?
| | Adoptive Transfer | 4 | 2008 | 224 | 0.140 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2022 | 351 | 0.140 |
Why?
| | Antibodies, Monoclonal | 2 | 2009 | 1428 | 0.140 |
Why?
| | Anxiety | 2 | 2022 | 1032 | 0.130 |
Why?
| | United States | 9 | 2025 | 14660 | 0.130 |
Why?
| | Parents | 2 | 2024 | 1355 | 0.130 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2016 | 15 | 0.130 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2013 | 46 | 0.130 |
Why?
| | Feces | 1 | 2019 | 479 | 0.130 |
Why?
| | Cesarean Section | 1 | 2018 | 185 | 0.130 |
Why?
| | Retrospective Studies | 7 | 2025 | 15564 | 0.120 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5417 | 0.120 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2007 | 187 | 0.120 |
Why?
| | Gastroenteritis | 1 | 2016 | 68 | 0.120 |
Why?
| | Anorexia Nervosa | 1 | 2017 | 86 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 5749 | 0.120 |
Why?
| | Patient Education as Topic | 1 | 2020 | 760 | 0.120 |
Why?
| | Disease Models, Animal | 5 | 2006 | 4279 | 0.120 |
Why?
| | HLA-DP beta-Chains | 1 | 2015 | 86 | 0.110 |
Why?
| | HLA-DR4 Antigen | 1 | 2014 | 78 | 0.110 |
Why?
| | Immunoglobulin G | 3 | 2021 | 886 | 0.110 |
Why?
| | Weight Gain | 1 | 2017 | 518 | 0.110 |
Why?
| | Case-Control Studies | 6 | 2019 | 3537 | 0.110 |
Why?
| | Homozygote | 1 | 2014 | 203 | 0.110 |
Why?
| | ROC Curve | 3 | 2013 | 545 | 0.110 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2013 | 429 | 0.100 |
Why?
| | Mice, Knockout | 8 | 2009 | 2999 | 0.100 |
Why?
| | International Cooperation | 2 | 2016 | 198 | 0.100 |
Why?
| | Child Development | 1 | 2017 | 471 | 0.100 |
Why?
| | Clonal Anergy | 1 | 2013 | 52 | 0.100 |
Why?
| | Young Adult | 5 | 2024 | 13126 | 0.100 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2012 | 11 | 0.100 |
Why?
| | Health Services Accessibility | 1 | 2020 | 976 | 0.100 |
Why?
| | Cohort Studies | 6 | 2025 | 5718 | 0.100 |
Why?
| | Mice, SCID | 4 | 2008 | 367 | 0.100 |
Why?
| | Antigen-Presenting Cells | 1 | 2013 | 156 | 0.100 |
Why?
| | B-Lymphocyte Subsets | 1 | 2013 | 75 | 0.100 |
Why?
| | Receptors, Calcitriol | 1 | 2012 | 55 | 0.100 |
Why?
| | Protein Precursors | 2 | 2003 | 132 | 0.100 |
Why?
| | Amino Acid Sequence | 3 | 2008 | 2145 | 0.100 |
Why?
| | Sweden | 3 | 2017 | 101 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 891 | 0.090 |
Why?
| | Breast Feeding | 1 | 2015 | 439 | 0.090 |
Why?
| | Colorado | 2 | 2024 | 4491 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1619 | 0.090 |
Why?
| | Bone Density | 1 | 2015 | 487 | 0.090 |
Why?
| | Treatment Outcome | 4 | 2024 | 10764 | 0.090 |
Why?
| | Heterozygote | 2 | 2016 | 292 | 0.090 |
Why?
| | Adenoviridae | 2 | 2019 | 193 | 0.090 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1799 | 0.090 |
Why?
| | Proinsulin | 3 | 2008 | 52 | 0.090 |
Why?
| | Plant Proteins | 1 | 2011 | 114 | 0.080 |
Why?
| | Immunoglobulin E | 2 | 2021 | 341 | 0.080 |
Why?
| | Feeding Behavior | 1 | 2015 | 648 | 0.080 |
Why?
| | Monitoring, Immunologic | 1 | 2009 | 23 | 0.080 |
Why?
| | Mice, Inbred C57BL | 8 | 2013 | 5744 | 0.080 |
Why?
| | Prothrombin Time | 2 | 2008 | 35 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2024 | 3272 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2006 | 913 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1323 | 0.080 |
Why?
| | Radioligand Assay | 1 | 2009 | 48 | 0.080 |
Why?
| | Bilirubin | 2 | 2008 | 97 | 0.080 |
Why?
| | Ammonia | 2 | 2008 | 62 | 0.080 |
Why?
| | Prediabetic State | 3 | 2009 | 253 | 0.080 |
Why?
| | Decision Support Techniques | 1 | 2013 | 418 | 0.080 |
Why?
| | Intracellular Fluid | 1 | 2008 | 27 | 0.080 |
Why?
| | Vaccines, DNA | 1 | 2008 | 32 | 0.080 |
Why?
| | Severity of Illness Index | 2 | 2008 | 2831 | 0.080 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 2008 | 12 | 0.070 |
Why?
| | Injections, Subcutaneous | 3 | 2004 | 154 | 0.070 |
Why?
| | Spleen | 3 | 2007 | 513 | 0.070 |
Why?
| | Biopsy, Needle | 2 | 2011 | 189 | 0.070 |
Why?
| | Hyperglycemia | 2 | 2008 | 346 | 0.070 |
Why?
| | Disease Progression | 6 | 2016 | 2750 | 0.070 |
Why?
| | Cholera Toxin | 1 | 2007 | 32 | 0.070 |
Why?
| | B7-1 Antigen | 2 | 2004 | 58 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2008 | 106 | 0.070 |
Why?
| | Forkhead Transcription Factors | 1 | 2008 | 190 | 0.070 |
Why?
| | Adult | 8 | 2023 | 37616 | 0.070 |
Why?
| | Self-Help Groups | 1 | 2007 | 35 | 0.070 |
Why?
| | Disease Susceptibility | 2 | 2020 | 344 | 0.070 |
Why?
| | Blood Glucose | 3 | 2006 | 2180 | 0.070 |
Why?
| | Genes, RAG-1 | 1 | 2006 | 12 | 0.060 |
Why?
| | Interferon-gamma | 2 | 2008 | 790 | 0.060 |
Why?
| | Crosses, Genetic | 1 | 2006 | 137 | 0.060 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 298 | 0.060 |
Why?
| | Antibody Formation | 1 | 2007 | 298 | 0.060 |
Why?
| | Education, Continuing | 1 | 2006 | 39 | 0.060 |
Why?
| | Logistic Models | 3 | 2017 | 2060 | 0.060 |
Why?
| | Intestine, Small | 1 | 2007 | 154 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2045 | 0.060 |
Why?
| | Pediatrics | 2 | 2016 | 1112 | 0.060 |
Why?
| | Age Factors | 3 | 2017 | 3290 | 0.060 |
Why?
| | Isoelectric Point | 1 | 2004 | 25 | 0.060 |
Why?
| | Autonomic Nerve Block | 1 | 2024 | 8 | 0.060 |
Why?
| | Antibodies, Heterophile | 1 | 2004 | 14 | 0.060 |
Why?
| | CD3 Complex | 1 | 2024 | 106 | 0.060 |
Why?
| | Survival Rate | 2 | 2007 | 1969 | 0.050 |
Why?
| | Molecular Sequence Data | 2 | 2008 | 2903 | 0.050 |
Why?
| | Immunity, Mucosal | 1 | 2004 | 97 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2009 | 846 | 0.050 |
Why?
| | Pancreatitis, Chronic | 1 | 2024 | 58 | 0.050 |
Why?
| | Canada | 1 | 2025 | 420 | 0.050 |
Why?
| | Nerve Block | 1 | 2024 | 74 | 0.050 |
Why?
| | Neonatal Screening | 1 | 2005 | 169 | 0.050 |
Why?
| | Ultrasonography, Interventional | 1 | 2024 | 142 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2003 | 248 | 0.050 |
Why?
| | Genetic Markers | 2 | 2015 | 344 | 0.050 |
Why?
| | Gene-Environment Interaction | 1 | 2024 | 194 | 0.050 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2004 | 564 | 0.050 |
Why?
| | Epitopes | 1 | 2005 | 480 | 0.050 |
Why?
| | Enkephalins | 1 | 2002 | 20 | 0.050 |
Why?
| | Pyridinium Compounds | 1 | 2002 | 26 | 0.050 |
Why?
| | Anemia, Pernicious | 1 | 2002 | 9 | 0.050 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2002 | 18 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1483 | 0.050 |
Why?
| | Animals, Newborn | 1 | 2004 | 843 | 0.050 |
Why?
| | Thyroid Diseases | 1 | 2002 | 36 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2008 | 2603 | 0.050 |
Why?
| | Addison Disease | 1 | 2002 | 43 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2003 | 368 | 0.050 |
Why?
| | Immunotherapy | 1 | 2007 | 640 | 0.050 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2002 | 69 | 0.050 |
Why?
| | Paracentesis | 1 | 2001 | 14 | 0.050 |
Why?
| | Oligopeptides | 1 | 2003 | 272 | 0.050 |
Why?
| | Gastroschisis | 1 | 2001 | 25 | 0.050 |
Why?
| | Ascites | 1 | 2001 | 46 | 0.050 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 2001 | 152 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 30 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 400 | 0.040 |
Why?
| | Prognosis | 2 | 2008 | 4018 | 0.040 |
Why?
| | Psychometrics | 1 | 2024 | 721 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 87 | 0.040 |
Why?
| | Survival Analysis | 1 | 2003 | 1319 | 0.040 |
Why?
| | Gene Expression | 1 | 2005 | 1499 | 0.040 |
Why?
| | Algorithms | 1 | 2008 | 1686 | 0.040 |
Why?
| | Self Report | 1 | 2024 | 825 | 0.040 |
Why?
| | Diet Records | 1 | 2019 | 83 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 288 | 0.040 |
Why?
| | Colonoscopy | 1 | 2001 | 247 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1697 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2001 | 316 | 0.040 |
Why?
| | Infant Formula | 1 | 2019 | 75 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2007 | 1568 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2017 | 2847 | 0.040 |
Why?
| | Rats | 2 | 2004 | 5628 | 0.040 |
Why?
| | Metagenomics | 1 | 2019 | 167 | 0.040 |
Why?
| | Histocompatibility Testing | 1 | 2017 | 126 | 0.030 |
Why?
| | Behavior Therapy | 1 | 2020 | 257 | 0.030 |
Why?
| | Population Surveillance | 1 | 2020 | 470 | 0.030 |
Why?
| | Rotavirus | 1 | 2016 | 20 | 0.030 |
Why?
| | Drug Utilization | 1 | 2017 | 170 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 623 | 0.030 |
Why?
| | Multiple Sclerosis | 1 | 2002 | 456 | 0.030 |
Why?
| | Rotavirus Vaccines | 1 | 2016 | 46 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2015 | 1455 | 0.030 |
Why?
| | Reference Values | 2 | 2011 | 817 | 0.030 |
Why?
| | Phenotype | 3 | 2015 | 3199 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2017 | 230 | 0.030 |
Why?
| | China | 1 | 2016 | 217 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 783 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1714 | 0.030 |
Why?
| | DNA Primers | 2 | 2008 | 513 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 615 | 0.030 |
Why?
| | Protective Factors | 1 | 2015 | 93 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2015 | 116 | 0.030 |
Why?
| | Vaccination | 1 | 2003 | 1378 | 0.030 |
Why?
| | Aggression | 1 | 2017 | 204 | 0.030 |
Why?
| | Family Health | 1 | 2016 | 197 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2019 | 559 | 0.030 |
Why?
| | Aging | 1 | 2005 | 1861 | 0.030 |
Why?
| | Cross-Cultural Comparison | 1 | 2015 | 90 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 520 | 0.030 |
Why?
| | Sleep Wake Disorders | 1 | 2017 | 283 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2011 | 1731 | 0.020 |
Why?
| | Intestines | 1 | 2015 | 359 | 0.020 |
Why?
| | Base Sequence | 2 | 2008 | 2180 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1281 | 0.020 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2013 | 130 | 0.020 |
Why?
| | Administration, Oral | 2 | 2004 | 808 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2013 | 239 | 0.020 |
Why?
| | Respiratory Tract Infections | 1 | 2016 | 396 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 738 | 0.020 |
Why?
| | Glutamate Decarboxylase | 1 | 2012 | 170 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2364 | 0.020 |
Why?
| | Sex Factors | 1 | 2017 | 2068 | 0.020 |
Why?
| | Species Specificity | 2 | 2004 | 584 | 0.020 |
Why?
| | Mothers | 1 | 2017 | 752 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 2013 | 425 | 0.020 |
Why?
| | Models, Genetic | 1 | 2013 | 605 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2010 | 53 | 0.020 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 391 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2009 | 11 | 0.020 |
Why?
| | Microchemistry | 1 | 2009 | 20 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 376 | 0.020 |
Why?
| | Pregnancy | 2 | 2018 | 6731 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2009 | 29 | 0.020 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 1 | 2009 | 13 | 0.020 |
Why?
| | Registries | 1 | 2017 | 2015 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2001 | 2624 | 0.020 |
Why?
| | Europium | 1 | 2009 | 2 | 0.020 |
Why?
| | Biotinylation | 1 | 2009 | 32 | 0.020 |
Why?
| | Streptavidin | 1 | 2009 | 14 | 0.020 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2008 | 82 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 1150 | 0.020 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2008 | 22 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 266 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2008 | 240 | 0.020 |
Why?
| | Plasmids | 1 | 2008 | 362 | 0.020 |
Why?
| | Cross-Priming | 1 | 2007 | 18 | 0.020 |
Why?
| | Cell Transplantation | 1 | 2007 | 37 | 0.020 |
Why?
| | Administration, Intranasal | 1 | 2007 | 90 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 182 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 337 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2007 | 286 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2013 | 4194 | 0.010 |
Why?
| | Integrin alpha Chains | 1 | 2004 | 24 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 2009 | 639 | 0.010 |
Why?
| | Environmental Health | 1 | 2004 | 48 | 0.010 |
Why?
| | Maternal-Fetal Exchange | 1 | 2004 | 165 | 0.010 |
Why?
| | T-Box Domain Proteins | 1 | 2003 | 98 | 0.010 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2003 | 64 | 0.010 |
Why?
| | Cell Line | 1 | 2008 | 2836 | 0.010 |
Why?
| | Age of Onset | 1 | 2004 | 518 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2002 | 75 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2512 | 0.010 |
Why?
| | Plasma Volume | 1 | 2001 | 19 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 522 | 0.010 |
Why?
| | Punctures | 1 | 2001 | 39 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1784 | 0.010 |
Why?
| | Glucagon | 1 | 2002 | 109 | 0.010 |
Why?
| | Major Histocompatibility Complex | 1 | 2002 | 227 | 0.010 |
Why?
| | Needles | 1 | 2001 | 59 | 0.010 |
Why?
| | Drainage | 1 | 2001 | 168 | 0.010 |
Why?
| | Safety | 1 | 2001 | 340 | 0.010 |
Why?
| | Alleles | 1 | 2002 | 888 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2004 | 826 | 0.010 |
Why?
| | Middle Aged | 1 | 2016 | 33200 | 0.010 |
Why?
| | Obesity | 1 | 2008 | 2975 | 0.010 |
Why?
| | Mutation | 1 | 2003 | 3953 | 0.010 |
Why?
|
|
Liu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|